iCAD
iCAD develops AI-powered breast cancer detection, density assessment, and short-term risk evaluation software for hospitals, breast imaging centers, and radiology practices. Its FDA-cleared ProFound AI suite uses deep-learning algorithms trained on 20M+ mammography images and was acquired by RadNet's DeepHealth subsidiary in July 2025.
- Company typePublic
- Founded2001
- HeadquartersNashua, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What iCAD does
iCAD is a medical technology company that develops AI-powered software for breast cancer detection, density assessment, and short-term risk evaluation, serving hospitals, breast imaging centers, and radiology practices. Founded in 1984 (and rebranded to iCAD in 2001 following a computer-aided detection focus) and headquartered in Nashua, New Hampshire, the company built its business around the ProFound Breast Health Suite, a modular platform of deep-learning algorithms that analyze 2D full-field digital mammography (FFDM) and 3D digital breast tomosynthesis (DBT) images. The core technology uses proprietary convolutional neural networks trained on more than 20 million images from 130 contributing centers across 15 countries, with the algorithms' fourth-generation release (ProFound AI Detection V4) introducing prior mammogram incorporation and ipsilateral lesion correlation. Products in the suite carry FDA 510(k) clearance, CE Mark, and Health Canada licensure and integrate with more than 50 PACS systems and all major mammography OEMs.
The company generates revenue primarily through enterprise software licensing of the ProFound AI suite, with recurring subscription elements and annual service agreements (Diamond Service Agreement, Technology Innovation Program). Its go-to-market is direct enterprise field sales targeting healthcare systems, supplemented by integration partnerships with platform vendors (GE HealthCare, Siemens Healthineers, Hologic, Fujifilm, Philips, Canon, Microsoft) and AI marketplace aggregators (CARPL.ai, Blackford, Sectra). The company divested its Xoft electronic brachytherapy business to Elekta AB in October 2023 for approximately $5.5 million, focusing operations entirely on the ProFound AI franchise, and operated as a public company on NASDAQ (ticker ICAD) with an installed base of more than 1,500 healthcare provider locations across 50+ countries.
In July 2025, iCAD was acquired by RadNet, Inc. through its DeepHealth subsidiary in an all-stock transaction valued at approximately $103 million ($3.61 per share), adding 66 AI research and development employees to the combined organization. Post-acquisition, iCAD operates as part of DeepHealth's radiology AI segment, with its breast imaging AI portfolio integrated into DeepHealth's end-to-end screening and diagnostic platform.
iCAD firmographics
Firmographics- Name
- iCAD
- Legal name
- iCAD, Inc.
- Website
- https://icadmed.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- iCAD develops AI-powered breast cancer detection, density assessment, and short-term risk evaluation software for hospitals, breast imaging centers, and radiology practices. Its FDA-cleared ProFound AI suite uses deep-learning algorithms trained on 20M+ mammography images and was acquired by RadNet's DeepHealth subsidiary in July 2025.
- Ownership category
- akta.pro rank
iCAD industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Software Publishers (51321)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where iCAD is headquartered
LocationHeadquarters
- HQ city
- Nashua
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
iCAD business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Software Licenses - ProFound AI Suite: Recurring software licenses for AI-powered mammography solutions including ProFound Detection, PowerLook Density Assessment, and ProFound AI Risk. Revenue model includes software subscription licenses with annual renewals, exposing the company to hospital capital expenditure cycles.
- Xoft Brachytherapy (Divested): Previously offered low-energy X-ray electronic brachytherapy technology. Business divested to Elekta AB in October 2023 for approximately $5.5 million.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Diamond Service Agreement |
| Subscription | Annual | Technology Innovation Program |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
iCAD product offering
Product offeringCore offering
iCAD develops and sells AI-powered medical imaging software for breast cancer detection, breast density assessment, and short-term breast cancer risk evaluation. Its flagship ProFound Breast Health Suite uses deep learning convolutional neural networks to analyze 2D and 3D mammography images, helping radiologists identify cancers earlier, reduce recall rates, and cut reading time. The software is licensed to hospitals, breast imaging centers, and radiology practices on a subscription basis with deployment via cloud, on-premises, or hybrid models.
Product overview
iCAD's ProFound Breast Health Suite is a modular platform-plus-products architecture comprising three primary AI-powered solutions: ProFound AI Detection (cancer detection), PowerLook Density Assessment (density scoring), and ProFound AI Risk (short-term risk evaluation). These modules share the ProFound Scorecard as a unified reporting interface and support deployment across 50+ PACS systems and multiple mammography manufacturers. The suite analyzes both 2D full-field digital mammography (FFDM) and 3D digital breast tomosynthesis (DBT), with versions supporting cloud, on-premises, and hybrid deployments. Secondary products include SecondLook for 2D mammography, VeraLook for colon health, and the PowerLook Advanced Mammography Platform as the underlying integration infrastructure.
Differentiator
Problem solved
Functional benefit
Brands
- ProFound AI: AI-powered breast cancer detection, density assessment, and risk evaluation suite for mammography.
- PowerLook
- SecondLook
- Xoft Axxent
Products and services
- ProFound AI Detection FDA-cleared deep-learning AI system for detecting malignant soft tissue densities and calcifications in 2D and 3D mammography. Provides concurrent-read workflow support with lesion scores and case scores for radiologist review. Targeted at hospitals, breast imaging centers, and radiology practices.
- PowerLook Density Assessment Automated breast density assessment solution using deep-learning algorithms to categorize breast density within BI-RADS 5th edition density categories for 2D and 3D mammography. Simplifies and standardizes density reporting across imaging workflows for radiologists and breast imaging centers.
- ProFound AI Risk Image-based short-term breast cancer risk prediction tool providing 1-2 year risk scores calculated from mammographic features and patient age. Achieves 2.4x greater accuracy than traditional risk models like Tyrer-Cuzick and Gail. Targeted at breast imaging centers and radiology practices for personalized screening decisions.
- SecondLook Computer-aided detection system for 2D mammography that automatically marks suspicious lesions and microcalcifications, providing a second-review capability for radiologists.
- VeraLook CT Colonography Computer-Aided Detection solution for colon health imaging analysis, targeted at radiology departments and imaging centers.
- PowerLook Advanced Mammography Platform (AMP) Integrated mammography platform supporting multiple AI solutions including detection, density assessment, and risk evaluation across vendor deployments.
Quantifiable outcome
- 23-27% increase in cancer detection rates per 1000 patients
- +6 more outcomes
Companies that use iCAD
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles3 records
iCAD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration28 records
AI capability8 records
Feature5 records
iCAD partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, minor and flagship.
- Google HealthcoreExpanded partnership to integrate Google's AI technology with iCAD's ProFound Breast Health Suite for 2D mammography use as independent reader. Joint development to enhance technology and expand access to millions of women and providers worldwide.
- CancerIQcoreIntegration partnership to combine AI-enabled breast imaging technology with best-in-class workflow platform for comprehensive breast health care solution. Aims to offer end-to-end risk assessment and care management.
- RAD-AIDminorAdvocacy partnership focused on improving global access to breast imaging and cancer detection, particularly in underserved regions through RAD-AID's international radiology development programs.
- GE HealthCarecorePlatform partnership for integration of ProFound AI with GE HealthCare imaging systems and PACS platforms. Multi-vendor compatibility enables deployment across GE mammography installations.
- Siemens HealthineerscorePlatform partnership for integration of ProFound AI with Siemens Healthineers mammography and imaging informatics solutions.
- HologiccoreIntegration partnership ensuring ProFound AI compatibility with Hologic mammography systems including Selenia Dimensions 3D tomosynthesis platform. Deep integration enables seamless workflow within Hologic workstation environment.
- Boca Raton Regional HospitalminorResearch partnership for clinical validation and algorithm diversity. Contributing data and clinical expertise to improve AI training datasets.
- Duke UniversityminorResearch partnership providing academic clinical validation and algorithm diversity for AI training datasets.
- Indiana UniversityminorResearch partnership led by Dr. James Nepute for clinical validation studies. Published peer-reviewed research on ProFound AI effectiveness in real-world clinical settings.
- Karolinska InstitutetcoreKey research partnership for development of ProFound AI Risk model. Professor Per Hall led validation studies published in Science Translational Medicine and Radiology journals. European validation of image-derived AI-based short-term risk model.
- University of PennsylvaniaminorResearch partnership including Prof. Emily Conant who has led multiple pivotal clinical studies on ProFound AI detection performance published in Radiology: Artificial Intelligence.
- RadNet / DeepHealthflagshipAcquisition completed July 17, 2025. RadNet's DeepHealth subsidiary acquired iCAD for approximately $103 million in all-stock transaction. Integration combines iCAD's AI breast imaging portfolio with DeepHealth's end-to-end screening and diagnostic solutions.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
iCAD competitors and assessment
Company assessmentDirect peers
- Volpara Health: Volpara is a direct peer offering AI-driven breast density assessment and cancer risk evaluation, directly overlapping with iCAD's PowerLook Density and ProFound AI Risk products.
- Lunit: Lunit is a direct peer in AI mammography with FDA-cleared Lunit INSIGHT MMG, competing for the same breast cancer detection workloads at hospitals and imaging centers globally.
- Hologic: Hologic is a direct peer and platform partner; it manufactures the dominant 3D mammography systems (Selenia Dimensions) and offers Genius AI detection, competing head-to-head with ProFound AI on the same installed base of Hologic workstations.
- Google Health: Google Health is both a strategic partner (integrating with ProFound) and a direct competitor in AI mammography, with its own clinical-grade breast cancer detection models targeting the same radiology workflow.
- Therapixel: Therapixel is a direct peer with MammoScreen 2.0, a CE-marked and FDA-cleared AI mammography detection solution competing in the same European and US hospital segment as ProFound AI.
- Densitas: Densitas is a direct peer in AI breast density and image quality analytics, integrating with iCAD but also selling standalone density solutions into the same mammography market.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers is both a platform integration partner and broad incumbent in mammography hardware and AI-Rad Companion radiology suite, offering competing AI breast imaging capabilities within a much larger portfolio.
- DeepHealth (RadNet): DeepHealth is iCAD's parent company following the July 2025 acquisition, operating a broader radiology AI portfolio including lung, prostate, and brain imaging that combines with iCAD's breast suite for an end-to-end screening offering.
- GE HealthCare: GE HealthCare is a platform partner and broad incumbent offering Senographe mammography systems and Edison AI platform, with competing breast AI capabilities across a broader imaging portfolio.
Emerging players
- Koios Medical: Koios Medical offers AI-based breast and thyroid ultrasound decision support, providing partial overlap with iCAD's breast imaging AI portfolio and listed as an iCAD integration partner through CARPL.ai and Blackford.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
iCAD social profiles
Digital presenceiCAD compliance and trust
Trust signalCompliance5 records
iCAD financial estimates
Financial estimateRevenue estimate
Valuation estimate
iCAD leadership team
Management profileNumber of profiles
Profiles2 records
iCAD funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iCAD M&A and investment
M&A and investmentM&A7 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iCAD
What does iCAD do?
iCAD develops and sells AI-powered medical imaging software for breast cancer detection, breast density assessment, and short-term breast cancer risk evaluation. Its flagship ProFound Breast Health Suite uses deep learning convolutional neural networks to analyze 2D and 3D mammography images, helping radiologists identify cancers earlier, reduce recall rates, and cut reading time. The software is licensed to hospitals, breast imaging centers, and radiology practices on a subscription basis with deployment via cloud, on-premises, or hybrid models.
Is iCAD a public or private company?
iCAD is a public company. It is classified as corporate owned and is currently acquired.
When was iCAD founded?
iCAD was founded in 2001. It employs 51 to 100 people.
Where is iCAD based?
iCAD is headquartered in Nashua, United States, in the North America region.
How does iCAD make money?
Two revenue lines are on record. Software Licenses - ProFound AI Suite is the primary driver. The others are xoft Brachytherapy (Divested).
Who are iCAD's main competitors?
Direct peers on record are Volpara Health, Lunit, Hologic, Google Health, Therapixel and Densitas. Broad incumbents are Siemens Healthineers, DeepHealth (RadNet) and GE HealthCare. Koios Medical is listed as an emerging player.
Does iCAD have an API?
No public API is recorded for iCAD.
What industry is iCAD in?
iCAD's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 51321 and its SIC code is 7372.